Evicenter
Tremfya (guselkumab) in Plaque psoriasis
Manufacturer
Janssen Biotech, Inc.
Prescribing information
Tremfya (opens in a new tab)
Questions
32
Last updated

All questions

Clinical trials: Tremfya (guselkumab) in plaque psoriasis

16 questions · 11 sources

Clinical trials

How were the Tremfya plaque psoriasis trials PsO1 and PsO2 designed?

Applies to Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Study results

How effective is Tremfya for plaque psoriasis at Week 16 (VOYAGE 1 and 2)?

Applies to Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

How fast does Tremfya improve plaque psoriasis?

Applies to Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

How many patients get completely clear skin on Tremfya at Week 24 (VOYAGE)?

Applies to Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Itch relief

Does Tremfya relieve psoriasis itch and other symptoms?

Applies to Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Comparisons

Tremfya vs Humira at Weeks 16 and 24: which cleared more skin in VOYAGE 2?

Applies to Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Tremfya vs adalimumab at Week 48: how did they compare in VOYAGE 1?

Applies to Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Note: The VOYAGE 1 Week 48 figures on the HCP page (84/115 and 53/115) match the Week 48 PASI 90 row for Trial PsO1 in label Table 6, which reports subjects from sites in the United States and Canada. In Table 6, the first two value columns are Trial PsO1 (TREMFYA, then adalimumab) and the last two are Trial PsO2; the label compares Week 48 results in Trial PsO1 only, so Trial PsO2 shows NA there.

Tremfya vs Cosentyx: which was more effective at Week 48 (ECLIPSE)?

Applies to Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Tremfya vs Cosentyx: how did they compare at Week 12 (ECLIPSE)?

Applies to Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Does Tremfya help after an inadequate response to Stelara (NAVIGATE)?

Applies to Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Maintenance of response

What happens when Tremfya is stopped after a response (PsO2 withdrawal)?

Applies to Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Long-term results

Does Tremfya keep working long term (5 years, VOYAGE 1)?

Applies to Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Long-term data

How many patients stay on Tremfya through 5 years?

Applies to Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Subgroup results

Does Tremfya work for scalp psoriasis?

Applies to Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

How effective is Tremfya for scalp, face, skin-fold, and genital psoriasis (SPECTREM)?

Applies to Adults with moderate plaque psoriasis, low body surface area involvement (2% to 15%), and high-impact site involvement (SPECTREM)

Pediatric efficacy

How effective is Tremfya in children with plaque psoriasis at Week 16?

Applies to Moderate to severe plaque psoriasis in pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy

Note: Trial PsO5 used weight-based doses for subjects under 70 kg; the approved pediatric dose is 100 mg for patients 6 years of age and older who weigh at least 40 kg.